At least 10 House lawmakers are backing a US trade panel’s probe of China’s biotech sector and related pricing practices, encouraging future executive action.
At least 10 House lawmakers are backing a US trade panel’s probe of China’s biotech sector and related pricing practices, encouraging future executive action.
In …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
US politicians push agencies to restrict research collaboration with China
Senate bill seeks to curb US reliance on China in drug industry
New bill takes aim at Chinese AI companies accused of copying American tech
Bipartisan lawmakers want to require U.S. to probe reliance on foreign-made drugs, ingredients
Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US
Business Brief (July 24): China, U.S. Explore Reciprocal Tariff Cuts
US lawmakers press Trump administration to close alleged semiconductor export loophole
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
BINSA, a bipartisan bill restricting US biotech deals with Chinese firms, is in limbo after failing to advance via the House…
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies.
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
